{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:44:51Z","timestamp":1759452291581,"version":"build-2065373602"},"reference-count":39,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T00:00:00Z","timestamp":1435190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Rituximab (RTX) is licensed for second\u2010line treatment of rheumatoid arthritis (RA) after first tumor necrosis factor (TNF) inhibitor failure. RTX is generally administered intravenously at 1 gm 2 weeks apart, and the retreatment is scheduled at the time of clinical relapse (regimen 1). A more intensive regimen is proposed with a fixed full cycle after 6 months (regimen 2) if remission is not reached. A cost\u2010effectiveness analysis (CEA) compared these 2 regimens of RTX administration in patients with longstanding RA based on data provided by an observational study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An observational retrospective study was conducted on 102 patients, enrolled in 3 hospitals and followed for \u226512 months. Forty\u2010seven patients followed regimen 1, while 55 patients followed regimen 2. A CEA based on a Markov model was conducted. A lifelong and social perspective was adopted. CEA was conducted for the entire cohort and for the 2 subgroups separately (patients with positive rheumatoid factor and\/or anti\u2013cyclic citrullinated peptide and failures to TNF inhibitors).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Results for the overall sample show at 10, 20, and 30 years that regimen 1 is less costly and associated with a higher quality of life compared to regimen 2. Probabilistic sensitivity analysis at 10 years estimated a probability of 95.1% for regimen 1 to be cost effective given a willingness to pay of \u20ac35,000\/quality\u2010adjusted life year, while for seropositive patients and for TNF failures it was estimated to be 92% and 92.7%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In longstanding RA, cost effectiveness of RTX retreatment at clinical relapse was found to be at least equivalent to the more intensive regimen proposed.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.22534","type":"journal-article","created":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T14:51:19Z","timestamp":1420642279000},"page":"947-955","source":"Crossref","is-referenced-by-count":4,"title":["Cost\u2010Effectiveness Analysis of Two Rituximab Retreatment Regimens for Longstanding Rheumatoid Arthritis"],"prefix":"10.1002","volume":"67","author":[{"given":"Luca","family":"Quartuccio","sequence":"first","affiliation":[{"name":"University Hospital Santa Maria della Misericordia Udine Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"di Bidino","sequence":"additional","affiliation":[{"name":"A. Gemelli Teaching Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"Catholic University of the Sacred Heart Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Schiavon","sequence":"additional","affiliation":[{"name":"University of Padua Padua Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Biasi","sequence":"additional","affiliation":[{"name":"University of Verona Verona Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvano","family":"Adami","sequence":"additional","affiliation":[{"name":"University of Verona Verona Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Punzi","sequence":"additional","affiliation":[{"name":"University of Padua Padua Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Americo","family":"Cicchetti","sequence":"additional","affiliation":[{"name":"Catholic University of the Sacred Heart Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"de Vita","sequence":"additional","affiliation":[{"name":"University Hospital Santa Maria della Misericordia Udine Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket266"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120573"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep314"},{"key":"e_1_2_7_5_1","article-title":"Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH\u2010RA, a global, observational, comparative effectiveness study","author":"Emery P","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta15140"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802321683"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090442"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq116"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker253"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2012.05.006"},{"key":"e_1_2_7_13_1","unstructured":"ISTAT. Demography in figures. URL:http:\/\/demo.istat.it\/. In Italian."},{"key":"e_1_2_7_14_1","unstructured":"Italian Agency for Pharmaceuticals. URL:http:\/\/agenziafarmaco.gov.it."},{"key":"e_1_2_7_15_1","unstructured":"Agenxia Italiana del Farmaco. Liste di rimborsabilita dei farmaci di fascia A. URL:http:\/\/www.agenziafarmaco.gov.it\/it\/content\/liste\u2010di\u2010trasparenza\u2010e\u2010rimborsabilit%C3%A0."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.665110"},{"key":"e_1_2_7_17_1","first-page":"45","article-title":"Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy","volume":"26","author":"Favalli EG","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep425"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.5.551"},{"volume-title":"Functional status and health\u2010related quality of life assessment in patients with rheumatoid arthritis. Working Paper 116","year":"2000","author":"Hawthorne G","key":"e_1_2_7_21_1"},{"key":"e_1_2_7_22_1","first-page":"91","article-title":"Proposal of guidelines for the economic evaluation of interventions","volume":"10","author":"Italian Association of Health Economics","year":"2009","journal-title":"Politiche sanitarie"},{"key":"e_1_2_7_23_1","first-page":"887","article-title":"OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis","volume":"30","author":"Gabriel S","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-009-0205-y"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462309090230"},{"issue":"2","key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3310\/hta13suppl2-04","article-title":"Rituximab for the treatment of rheumatoid arthritis","volume":"13","author":"Bagust A","year":"2009","journal-title":"Health Technol Assess"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22269"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22116"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203480"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204544"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201117"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200170"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126714"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X06297389"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205011"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R203"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-eular.3994"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.04.012"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.027565"},{"key":"e_1_2_7_40_1","unstructured":"CurrieG DonaldsonC McIntoshE.Cost effectiveness analysis and the societal approach: should the twain ever meet? Institute of Health Economics. Working Paper 00\u20103. URL:http:\/\/www.ihe.ca\/publications\/library\/archived\/cost\u2010effectiveness\u2010analysis\u2010and\u2010the\u2010societal\u2010approach\u2010should\u2010the\u2010twain\u2010ever\u2010meet\/."}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.22534","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.22534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:50:45Z","timestamp":1759416645000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.22534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,25]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1002\/acr.22534"],"URL":"https:\/\/doi.org\/10.1002\/acr.22534","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"type":"print","value":"2151-464X"},{"type":"electronic","value":"2151-4658"}],"subject":[],"published":{"date-parts":[[2015,6,25]]}}}